Redwood Park Advisors LLC Sells 893 Shares of Pfizer Inc. $PFE

Redwood Park Advisors LLC reduced its position in shares of Pfizer Inc. (NYSE:PFE) by 33.4% during the 2nd quarter, HoldingsChannel.com reports. The firm owned 1,783 shares of the biopharmaceutical company’s stock after selling 893 shares during the quarter. Redwood Park Advisors LLC’s holdings in Pfizer were worth $43,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently made changes to their positions in the company. GKV Capital Management Co. Inc. bought a new stake in Pfizer during the 1st quarter worth approximately $27,000. Curio Wealth LLC grew its stake in shares of Pfizer by 36,600.0% in the second quarter. Curio Wealth LLC now owns 1,101 shares of the biopharmaceutical company’s stock worth $27,000 after purchasing an additional 1,098 shares during the last quarter. North Capital Inc. bought a new stake in shares of Pfizer in the first quarter worth $28,000. Bayforest Capital Ltd bought a new stake in shares of Pfizer in the first quarter worth $28,000. Finally, Harbor Asset Planning Inc. bought a new stake in shares of Pfizer in the 2nd quarter valued at about $29,000. 68.36% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

A number of equities research analysts have commented on PFE shares. Citigroup upped their price target on Pfizer from $25.00 to $26.00 and gave the company a “neutral” rating in a research report on Wednesday, August 6th. Wall Street Zen cut Pfizer from a “buy” rating to a “hold” rating in a report on Sunday, September 28th. Morgan Stanley reduced their target price on Pfizer from $33.00 to $32.00 and set an “equal weight” rating on the stock in a report on Friday, October 10th. Bank of America upped their price objective on shares of Pfizer from $28.00 to $30.00 and gave the company a “neutral” rating in a research note on Friday, October 3rd. Finally, UBS Group reaffirmed a “neutral” rating and issued a $28.00 price objective on shares of Pfizer in a research note on Wednesday, October 1st. Two analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating, eleven have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Hold” and an average price target of $28.13.

Pfizer Price Performance

Pfizer stock opened at $24.76 on Tuesday. The stock has a market capitalization of $140.75 billion, a price-to-earnings ratio of 13.17, a PEG ratio of 0.82 and a beta of 0.55. Pfizer Inc. has a 52-week low of $20.92 and a 52-week high of $29.17. The stock’s 50 day moving average price is $24.86 and its two-hundred day moving average price is $24.21. The company has a debt-to-equity ratio of 0.65, a quick ratio of 0.85 and a current ratio of 1.16.

Pfizer (NYSE:PFE) last issued its earnings results on Tuesday, August 5th. The biopharmaceutical company reported $0.78 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.58 by $0.20. The business had revenue of $14.65 billion for the quarter, compared to analyst estimates of $13.43 billion. Pfizer had a net margin of 16.84% and a return on equity of 21.42%. Pfizer’s revenue was up 10.3% on a year-over-year basis. During the same period in the prior year, the firm earned $0.60 earnings per share. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. On average, equities analysts predict that Pfizer Inc. will post 2.95 earnings per share for the current year.

Pfizer Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Monday, December 1st. Stockholders of record on Friday, November 7th will be given a dividend of $0.43 per share. This represents a $1.72 dividend on an annualized basis and a dividend yield of 6.9%. The ex-dividend date of this dividend is Friday, November 7th. Pfizer’s dividend payout ratio is 91.49%.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.